Cell Marque Immunohistochemistry Antibodies and Reagents [Selective Therapy] - HSA Registration DE0016708
Access comprehensive regulatory information for Cell Marque Immunohistochemistry Antibodies and Reagents [Selective Therapy] in the Singapore medical device market through Pure Global AI's free database. This CLASS C IVD medical device is registered under HSA registration number DE0016708 and owned by CellMarque Corporation. The device was registered on December 30, 2014.
This page provides complete registration details including product owner information, registrant details, importer information, and regulatory compliance data from the official Singapore HSA medical device database. Pure Global AI offers free access to Singapore's complete medical device registry, helping global MedTech companies navigate HSA regulations efficiently.
The Cell marque monoclonal and polyclonal antibodies, and ancillary IHC reagents are intended for qualified laboratories to qualitatively identify by light microscopy, the presence of associated antigens in sections of formalin fixed, paraffin embedded or frozen tissue sections using manual or automated IHC test methods. Use of this antibody is indicated as an aid in selective therapy or therapy management of human tumors within the context of the parent's clinical history and other diagnostic tests evaluated by a qualified pathologist or physician.